Guard Therapeutics International AB (OSTO:GUARD) Research & Development: kr69.27 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:GUARD Guard Therapeutics International AB OSTO:GUARD
25 GF Score
Price kr1.58
! 1 Warning Sign
View Full Analysis

What is Guard Therapeutics International AB Research & Development?

Guard Therapeutics International AB OSTO:GUARD +1.15% 25 Research & Development is kr69.27 Mil as of Mar. 2026. GuruFocus rates OSTO:GUARD with a GF Score™ of 25/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Guard Therapeutics International AB's Research & Development for the three months ended in Mar. 2026 was kr3.87 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was kr69.27 Mil.

Guard Therapeutics International AB  (OSTO:GUARD) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Guard Therapeutics International AB Research & Development Related Terms

Guard Therapeutics International AB Research & Development Historical Data

* Premium members only.

The historical data trend for Guard Therapeutics International AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guard Therapeutics International AB Research & Development Chart

Guard Therapeutics International AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 75.33 104.81 105.77 90.33 96.00

Guard Therapeutics International AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.60 29.74 23.15 12.51 3.87
OSTO:GUARD
25GF Score
Guard Therapeutics International AB OSTO:GUARD
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guard Therapeutics International AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr69.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr69.27 Mil mean?
Guard Therapeutics International AB (OSTO:GUARD) has a Research & Development of kr69.27 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Guard Therapeutics International AB and its competitors.
Is Guard Therapeutics International AB's Research & Development too high?
Guard Therapeutics International AB's current Research & Development is kr69.27 Mil. Overall, Guard Therapeutics International AB has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Guard Therapeutics International AB's Research & Development compare to VRTX and REGN?
Guard Therapeutics International AB's Research & Development of kr69.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Guard Therapeutics International AB and its competitors. Guard Therapeutics International AB's current Research & Development is kr69.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guard Therapeutics International AB stock overvalued right now?
Guard Therapeutics International AB (OSTO:GUARD) has a current Research & Development of kr69.27 Mil. The current Research & Development is kr69.27 Mil. Guard Therapeutics International AB's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Guard Therapeutics International AB (OSTO:GUARD), the current Research & Development is kr69.27 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Guard Therapeutics International AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Guard Therapeutics International AB is engaged in developing and commercializing the lead drug candidate ROSgard, and thereby contribute to the better and less harmful treatment of acute kidney injuries.
25GF Score

Get the complete analysis for OSTO:GUARD

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.58
Price